RE: Q&A16 Nov 2020 18:02
PAH00 - fully agree.
Whilst it is irritating that the presentation was not able to show an Avacta product, the huge probability (IMHO) is that when the Avacta LFT comes to market it will be of significantly higher quality and will have the potential to become the industry standard .
There is such vast international demand for high quality, fast tests that Avacta will have no difficulty in selling whatever they can make.
So far, the criticism of available LFT’s is usually that they are not good enough to detect accurately the asymptomatic cases. Hopefully, the Avacta test will lay that criticism to rest.
The need for such tests will endure for years to come for many reasons......just one of which is that even vaccinated individuals (at least 50% of them) will be liable to become infected with the virus sufficiently to shed and spread it, causing others to become infected even when they themselves may have few, or no, symptoms . Testing will be needed to identify those individuals.
It would be a bonus to hear some positive news soon from the company - no doubt every effort is being made to achieve that.